Chief Scientific / Medical Officer (Stealth Photonic Bio-sensing Venture)

You own the clinical and scientific story end-to-end. Investors, design partners, and clinical collaborators need to hear the biology from someone who has lived it. You decide which biomarkers and clinical questions we go after first, and how the company's scientific roadmap evolves over years 1, 3, and 5.

What you'll do

• Scientific narrative: the biomarker → clinical decision story behind every commercial bet, investor pitch, and grant.
• Clinical and research partnerships: design-partner relationships across haematology, oncology, infectious disease, transplant, and translational research.
• Assay and panel strategy: which markers we ship first, the rationale a clinician will accept, and the evidence we need to gather to support each claim.
• Clinical evidence and trial design: working with regulatory consultants to map the path through pre-submission, CLIA-Waiver / IVDR, and pivotal study.
• Clinical Advisory Board: recruit and chair a small specialist board across the priority therapy areas.
• Scientific authorship: publications and grant submissions that build biological credibility.
• Future scientific direction: as the company's scientific roadmap evolves, you frame the clinical and translational opportunities that justify each step.

What you'll need

• MD, PhD, or DPhil in haematology, immunology, clinical pathology, or cancer immunology.
• 5–10 years industrial experience as CMO/CSO at a diagnostics, cytometry, or cell therapy company or an equivalent translational-research portfolio with at least one prior spinout.
• Have personally designed multiparameter immunophenotyping panels and seen them translated into a clinical decision someone acted on.
• Fluent in what an oncologist does with a CTC count, what a haematologist does with MRD, what an HIV physician does with a CD4/CD8 ratio.

Nice to have

• Active clinical practice (1 day/week NHS or honorary contract).

What they offer

• Founding team-level equity.
• Salary calibrated to round size and role's market reality.